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A tumor is a heterogeneous population of cells that provides an environment in which every cell resides in a
microenvironmental niche. Microscopic evaluation of tissue sections, based on histology and immunohis-
tochemistry, has been a cornerstone in pathology for decades. However, the dawn of novel technologies to
investigate genetic aberrations is currently adopted in routine molecular pathology. We herein describe our
view on how recent developments in molecular technologies, focusing on proximity ligation assay and padlock
probes, can be applied to merge the two branches of pathology, allowing molecular profiling under histologic
observation. We also discuss how the use of image analysis will be pivotal to obtain information at a cellular
level and to interpret holistic images of tissue sections. By understanding the cellular communications in the
microecology of tumors, we will be at a better position to predict disease progression and response to therapy.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Progress is not a process that proceeds with a
steady pace; it takes leaps when opportunities arise.
In science, these leaps spur out of novel views
that contradict existing paradigms or emerging
technologies, which enable new types of analysis.
In biological and medical research, new instruments
and technologies have been key elements to explore
unknown territories. The development of the
microscope provided researchers with the ability to
view microorganisms and cells, which has been
instrumental for the understanding of how we
humans and all other organisms are built up. The
ability to visualize the micro-cosmos incited the
development of dyes that stain cells and make them
easier to see and targeted reagents to selectively
visualize cells that share certain features, such asAuthors. Published by Elsevier Ltd. This
rg/licenses/by-nc-nd/4.0/).expression of a specific protein. Immunohistochem-
istry and immunofluorescence that are utilizing
enzyme or fluorophore-labeled antibodies targeted
against specific proteins were developed to
selectively stain cells or tissue sections in order to
evaluate expression levels of the targeted protein in
individual cells. With the addition of more and more
antibodies, we now have a map of the human tissue
proteome [1]. Microscopic analysis is a cornerstone
in the field of pathology and is routinely used by
pathologists to provide diagnosis. Even today,
immunohistochemistry is the ideal method to classify
precise lineage affiliations and, sometimes, also to
define targeted therapeutic options. Another exam-
ple on how a technology has spurred our increasing
knowledge in biology and medicine is DNA-based
technologies, such as PCR and sequencing [2,3].
Having a detailedmap of the human proteome, as well
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patients, has allowed identification of genomic aberra-
tions in inherited genetic disorders and somatic
diseases, such as cancer. These types of analysis
are currently being adopted in routine diagnostics with
extended impact on relevant therapeutic decisions.
The two examples mentioned above differ in spatial
resolution: while analysis by microscopy provides
information resolved to single cells, sequencing of
DNA obtained from a pool of cells or a piece of tissue
provides an average measurement over all cells in the
sample. They differ also in other aspects: immunohis-
tochemistry is still evaluated by skilled pathologists
and mainly performed in singleplex, that is, staining
with one antibody per slide, while sequencing is highly
automated and performed at extreme multiplexing, up
to whole genome sequencing.
We are now approaching a point in history when
we will have the opportunity to take another great
leap forward. Here we will discuss how microscopic
analysis can be performed at greater levels of
multiplexing, incorporating genotyping and evalua-
tion of expression levels of both proteins and
mRNAs and also providing possibilities to interro-
gate protein interactions and post-translational
modifications (PTMs), hence also monitoring signal
pathway activity status. Furthermore, utilizing auto-
mated image analysis will provide pathologists with
tools to comprehend the vast complexity of data and
also enable comparisons of how images are
interpreted at different laboratories and will validate
the diagnosis of each individual patient.The Tumor Microenvironment
The interplay between the different cell types in a
multicellular organism has been shaped during
millions of years of evolution. Each organ and tissue
in a human presents a unique microenvironment in
which the different cell types reside in highly
specialized niches. The microecology in a tumor is
not a static situation and how well a cell adapts to
changes in environment will have consequences on
differentiation, growth and survival of the cells.
Analogies toward the ecology in nature can be a
way to approach the situation in vivo, although we
are aware that this may oversimplify the complexity
of the problem. It is, however, an approach that helps
understanding tumorigenesis and how cancer cells
respond to, and shape, their microenvironment.
Cancer can be seen as evolution of a new species
that tries to occupy a new microenvironmental niche
and will be subjected to Darwinian selection during
this process [4]. Theoretically a more immature cell
type, with less epigenetic regulation, is more capable
of differentiating into a phenotype that can survive
and prosper in a new microenvironment [5,6]. As
an analogy, the introduction of rabbits in Australiaprovided them with a compatible environment but
within a new ecological context: without predators to
control the population. This allowed them to proliferate
rapidly. Such opportunistic and ecology-dependent
behavior can also be seen for cells under some
“spectacular” experimental conditions where trans-
plantation of embryonic stem cells out of context
results in teratoma formation [7]. Introduction of
teratoma cells into blastocysts can produce healthy
mosaic mice [8]. Teratomas are tumors originating in
germ cells and have the capacity to differentiate in
tissues from three germ cell lineages—endoderm,
mesoderm and ectoderm. The ecologic dependence
is of particular interest for stem cell therapy where
similar problems do occur, for instance, occurrence of
teratomas [9,10]. There are also several reports on the
maintenance of malignant cells in individuals that do
not have clinical symptoms, indicating that they may
be kept in control by the microecology [11]. The
microenvironmental control of cellular fate, including
immune cells in the microenvironment, is a field that
very likely will have huge impacts on future oncology,
including new cancer treatment modalities [12,13].
As cancer cells proliferate, they compete with
normal cells for both space and access to nutrients,
shaping the microenvironment to their needs.
Cancer cells promote angiogenesis through secre-
tion of pro-angiogenic growth factors that stimulate
sprouting of endothelial cells from nearby vessels or
by co-opting pre-existing vasculature [14]. Vessels
are required to support the cancer cells with oxygen
and nutrients, represent a route for metastasis and
provide a niche for cancer stem cells [15]. However,
tumor vasculature is often malfunctioning and
hyper-permeable, leading to poor oxygenation and
high interstitial fluid pressure in the tumor [16]. Low
oxygen tension in combination with extracellular
matrix components and cytokine production in the
over-populated microenvironment may induce can-
cer cells to undergo epithelial-to-mesenchymal
transition: a process in which they loose their cell–
cell adhesion and polarity to acquire migratory traits
for the invasion of surrounding tissues [17,18]. They
can then migrate through the surrounding tissue or
utilize blood vessels or the lymphatic system as
rivers to rapidly reach other sites. To achieve
vascular invasion (intravasation), cancer cells tend
to migrate in clusters, a process known as collective
migration [19]. Most cancer cells succumb in
circulation, mostly if they travel as isolated cells,
but some are washed up on nearby or distal shores.
In fact, traveling and homing to distant sites will
depend on clustering of cells in circulation to be
successful [20]. Again, microenvironment seems to
play a crucial role all along the process of carcino-
genesis and cancer progression, even at the very
level of cell–cell interactions. In agreement with this,
it has been reported that peritoneovenous shunts,
draining intractable carcinomatous ascites directly
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necessarily very successful to generate metastasis
despite the large amount of malignant cells intro-
duced in circulation [21]. When the cells exit from
circulation, extravasation followed by mesenchy-
mal-to-epithelial transition is needed to revert to
their original phenotype. As the cancer cells have
evolved in a specific microecology, in the site of the
primary tumor, their chance of surviving a journey to
an adjacent site of the same organ is better than if
they encounter a more different microenvironment. It
has been suggested that cancer can grow in the
primary site through homing to the same organ in a
process called self-seeding [22]. It has also been
suggested that cancer cells try to reshape the
microenvironment of distant organs by secreting
exosomes containing proteins and RNA that affect
the phenotype of the retrieving cells [23]. Once the
cancer cells have succeeded in this, they may
proliferate and form metastasis.Cancer Development
The development of a cancer is in most cases a
stepwise process, requiring mutations in several
oncogenes and tumor suppressor genes [24],
together with epigenetic alterations. Although these
changes alter the phenotype of the cancer cells, they
still carry most of the epigenetic signature from the
differentiation lineage they derived from, and hence,
the properties of different types of cancer differ
depending on origin and mutational spectrum [25].
Exceptions are cancers derived from metaplasia, a
transdifferentiation of an adult tissue into a different
adult tissue but in a mislocalized setting. In these
cases, a differentiation reprogramming occurs be-
fore carcinogenesis or at very early cancer stages
[26,27]. Over the last decades, this information has
been used to further subgroup different classes of
cancers that share phenotypic and genetic features.
The more parameters used for the grouping,
the more subgroups will emerge. Also, the hetero-
geneity of the details makes it difficult to evaluate
the prognostic and therapeutic implications since
large multicentric studies will be necessary to attain
statistical significance. At the limit, when taking into
account the unique genetic makeup of each individ-
ual, the potential influence of the tumor microenviron-
ment and the mutational and epigenetic status of the
cancer cells, all tumors will be unique. No patient will
be identical with another, although they will share
some features. In addition, the tumors often consist of
several subclones with shared and unique mutations
[28], which imply that even a single tumor will contain
cancer cells with different cellular programs and
abilities to interact with the microenvironment, utilizing
different niches or competing with other clones within
a niche [4].Most treatment options for cancer cells aim at killing
proliferating cells, for example, by disturbing replica-
tion or targeting a signaling pathway to which the
cancer cells have become addicted to, due to
activating mutations omitting the need for upstream
signals. Although initial response may be very
prominent, the cancer cells will often develop resis-
tance and come back with a vengeance [29]. With the
more recent use of targeted therapy, we have seen
that cells can acquire novel mutations in order to
evade succumbing to therapy. Alternatively, the
alterations in the microecology caused by the
treatment, that is, elimination of sensitive clones,
create an opportunity for subclones harboring advan-
tageous mutations to expand and fill the now empty
niche or that heterogeneity in transcription facilitates
survival of subpopulations [30]. However, another
explanation is that the cancer cells rewire the
intracellular networks to circumvent the blockage at
the targeted node [31,32]. The escape mechanisms
are not well understood and future pathology will need
to monitor how treatment affects both the cancer cells
and the microecology in the tumors, namely, the
variable composition in terms of different sorts of pro-
and anti-tumoral lymphocytes andmacrophages. The
inflammatory response brought by a severe killing of
cancer cells may also stimulate quiescent subclones
with a more stem-cell-like phenotype, so called
cancer-initiating cells, and their progeny will be able
to fill the void in the tumormicroecology created by the
treatment. It is possible that the strategy of eradicating
the cancer cells fuels tumor evolution, and alternative
approaches to control the microecology and block the
proliferation of cancer cells, without killing them,would
be a substitute. High content analysis will be essential
in order to understand the tumor ecology, providing
information on what signaling pathways are active in
different cell types in a tissue and how this correlate
with cell–cell communication and genotype. It is clear
that complexitywill increase, by the gain in insight both
at the cancer cell and at the microenvironment levels,
and that a coordinated view on the whole network of
intercellular communication will be needed.Method Requirements for Analysis
of Tumors
There are four desirable key features of methods
for surveillance of tumor microecology. First of all
is multiplexing: in parallel, many different types of
information are needed to decode the delicate
interplay between cells. Second, analytical methods
have to target functional aspects of the signaling
networks—such as protein–protein interactions,
PTMs of proteins and expression of target genes.
Third, the methods will have to be able to determine
the genotypes, identifying a spectrum of different
mutations. Finally, the methods should be spatially
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ture in order to determine intratumor heterogeneity
and intercellular and intracellular signaling.
From the early days of immunohistochemistry,
pathologists know that many tumor markers are
expressed in the invasive front of tumors andmodulate
matrix remodeling. These modifications have
recently been ascribed to the process of epithelial-to-
mesenchymal transition. For nucleic acids, it is
currently possible to perform single cell analysis of
multiple targets, including sequencing of whole tran-
scriptomes from individual cells [33]. For proteomics,
however, this is a much more challenging task, as
efficiency of bothmass spectrometry and affinity-based
technologies is far fromdetecting singlemolecules. The
throughput is a limiting factor using microdissected
samples; currently, analysis of thousandsof cellswould
not be practical. To achieve this, it may be more
straightforward to perform the analysis directly on the
tissue sections, using non-targeted approaches, that is,
imaging mass spectrometry [34,35], or targeted ap-
proaches, utilizing labeled antibodies for example. The
number of different fluorophores that simultaneously
can be visualized is limited due to overlaps in excitation
and emission spectra of the different fluorophores
used. A way to increase the number of measured
parameters is to use antibodies labeled with mass tags
[36], expanding the number of possiblemeasure points
in a stained tissue [37,38]. Another way to increase
multiplexing is to perform multiple staining with
sequential readout. For this approach, the analysis
has to be non-destructive; hence, mass cytometry
could not be used. Instead, one can rely on analysis
using fluorescence microscopy for example. By per-
forming repetitive cycles of staining, imaging and
bleaching, with the use of a single fluorophore to label
all the different antibodies, we can perform highly
multiplexed analysis [39]. With the use of this strategy,
the number of analyzed parameters will increase
linearly, reflecting the number of cycles performed
and the number of fluorophores used. To increase
multiplexing even further, with a concomitant reduction
of number of performed cycles, a strategy is to barcode
the different molecular objects identified, using the
information obtained in each cycle providing an
exponential increase of identities, that is, number of
fluorophores to the power of the number of cycles. The
four different bases investigated at each position will be
reported with a unique fluorophore by utilizing se-
quencing in situ to decode identities. Hence, sequenc-
ing of four bases will obtain 44 = 256 different
signatures [40]. The different strategies to increase
multiplexingare heavily dependent onadvanced image
analysis approaches and will be described further in
subsequent section.
The next methodological hurdle to detect signaling
network activity is to target protein interactions and
PTMs. The cellular signaling network relays informa-
tion via protein–protein interactions. All proteins havethe ability to bind all others, which interactions that are
most present depend on affinities and local concen-
tration [41]. As a consequence of functional interac-
tions, changes in conformationmayoccur due toPTMs
or complex formation with partner proteins. This will
change their affinity toward other proteins, determining
the possibility to engage in further/novel protein
interactions. Translocation of the proteins in active
conformation to other compartments of the cell, for
example, from the plasma membrane to the nucleus,
will also have consequences on which interactions
may occur, as the local concentration of interaction
partners differ in between cellular compartments.
Which protein–protein interactions are present in a
cell, the amounts and location can be seen as the
interface between the genetic/epigenetic composition
of the cell and external cues, reflecting the activity
status of the cells. There is a large repertoire of affinity
reagents targeting PTMs, and these reagents can be
used to investigate whether, or not, a protein is in a
functionally active conformation. By using a panel of
such reagents, it is possible to determine functional
states of individual cells within a population. However,
single recognition assays suffer from problems with
cross-reactivity. All affinity reagents are destined to
bind multiple targets, with different affinities. To
increase selectivity, we can use assays based on
dual, or multiple, recognition events. An additional
advantage with such a strategy is that it also facilitates
analysis of protein complexes, where two or more
affinity reagents bind to different proteins within a
protein complex. There are several ways to determine
dual binding events. Themost straightforwardway is to
label the different affinity reagents with unique
fluorophores and determine colocalization of the
staining. However, this will require very sophisticated
microscopes operating below diffraction limit with
sensitivities to detect single fluorophores. At present,
this is extremely challenging to perform on tissue
sections. An alternative approach is to use the
proximal binding as a functional requirement to
generate a signal. This strategy is used in the Förster
resonance energy transfer in which a donor fluoro-
phore only can transfer the energy to an acceptor
fluorophore if they are in close proximity, within a few
nanometers. By determining emission spectra
from donor and acceptor, or change in lifetime, we
can record proximity between fluorophore-labeled
antibodies [42].Methods for Surveillance of
Tumor Microecology
A method that retains the dependency of proximal
binding of antibodies and provides a mean for signal
amplification is the in situ proximity ligation assay
(PLA) [43] (Fig. 1a) (for review of different designs, see
Koos et al. [44]). This technology utilizes DNA
Fig. 1. Principle of in situ PLA
and padlock probes. (a) For detection
of protein–protein interactions, the in
situ PLA requires two proximity
probes to bind to their respective
targets. If the probes bind in close
proximity, two circularization oligonu-
cleotides can be hybridized and ligat-
ed in order to form a circular DNA
molecule. In the ensuing RCA, this
DNAmolecule can be amplified as an
extension of one of the proximity
probes. The so-generated RCA prod-
uct can be visualized by hybridization
of fluorophore-labeled detection oligo-
nucleotides. (b) In order to detectRNA
molecules via padlock probes, a
primer oligonucleotide that partly con-
sists of locked nucleic acids needs to
hybridize to the RNA molecule. This
primer will be extended in an in situ
reverse transcription upon which the
RNA part of the DNA/RNA hybrid is
degraded and a padlock probe is
hybridized to the cDNA. Importantly,
the RNA bound to the locked nucleic
acids part of the primer is not degrad-
ed, providing a link to the rest of the
RNA molecule. The padlock probe is
then ligated onto the target and
amplified using RCA. Visualization of
the RCA product is achieved by
hybridization of fluorophore-labeled
detection oligonucleotides.
2017Review: Surveillance of Tumor Microecologyoligonucleotides conjugated to antibodies (proximity
probes) to provide a template for ligation of subse-
quently added circularization DNA oligonucleotides.
The ligation will only generate circular products if the
proximity probes bind in close proximity. The length
and orientation of the oligonucleotides, as well as the
size of the affinity reagents, determine the distance
requirement for in situ PLA. Once a circular ligation
product is formed, it can be amplified by rolling circle
amplification (RCA). The DNA oligonucleotide on one
of the proximity probeswill act as a primer for RCA and
the RCA product will hence be an elongation of that
proximity probe, a concatemer of several hundreds of
repeats, complementary to the circular ligation prod-
uct. By hybridizing fluorophore-labeled detection DNA
oligonucleotides to theRCAproduct, wewill stain each
single molecule with several hundred fluorophores.
The signal amplification provided by RCA facilitates
detection of single ligation events. However, the size of
an RCA product is approximately 1 μm in diameter,
which limits the number of events that can be recorded
in a single cell. To increase the dynamic range, we can
use alternative circularization oligonucleotides in a set
ratio and can detect them by different fluorophore-
labeled detection oligonucleotides [45]. When one
identity saturates the cell, a more diluted one will beanalyzable. In situPLA can be used for visualization of
endogenous protein–protein interactions [43], PTMs
[46–49] and protein–nucleic acid interactions [50–52],
and the generation of discrete signals facilitates
enumeration by digital image processing and analysis.
The ability to determine protein interactions and PTMs
in fixed tissue sections may facilitate the use in routine
pathology. A specific application where in situ PLA
has successfully overcome a technical limitation is the
identification of mucin glycoforms [53], the major
cancer biomarkers used in the clinical setting. In fact,
till recently, the protein components and the glycan
components of mucins were impossible to get into a
compound glycoprotein profile. Moreover, the com-
bined profile is giving hope for increasing sensitivity
and specificity to the classical approaches. Other
examples are EGFR/HER interactions [54–56]
and PDGFR phosphorylation [57,58]. It has to be
mentioned that in situ PLA is a targeted approach, in
pairwise interactions that are monitored. Selecting
potential interaction partners relies on work performed
on protein–protein interaction networks by other
methods that are more suitable for screening pur-
poses, such as two-hybrid assays [59–61].
For analysis of nucleic acids, the stringent
requirement of circularizing can be used to provide
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linear DNA oligonucleotides designed so that hybrid-
ization of a padlock probe with its target sequence
will bring the 5′- and the 3′-ends of the padlock probe
into juxtaposition [62] (Fig. 1b). Only correctly bound
padlock probes would thus be possible to be ligated
into a circular conformation, such that a mismatch in
the junction will abolish, or prominently reduce, the
ligation efficiency. Double-stranded DNA has to be
converted into single-stranded DNA using, for in-
stance, restriction enzymes and exonucleases prior
to padlock probing, in order to allow hybridization of a
padlock probe to a DNA target [63]. To probe RNA
molecules, we require the use of reverse transcriptase
to generate cDNA templates for hybridization [64].
Once the padlock probe has been ligated into a circular
conformation, its ligation template (i.e., the single-
stranded DNA to which the padlock probe hybridized
to) can act as a primer for RCA to generate a localized
product that can be visualized with hybridization of
fluorophore-labeled detection oligonucleotides. The
method can be used to genotype mRNA [65]. As both
in situPLAand padlock probes utilizeRCA to generate
an amplified signal, the twomethods can be combined
to provide measurements of all steps in signaling
networks [66,67], that is, from surface receptors down
to expression of target genes. In addition, both
methods are well suited for multiplexing [40,68] and
can be read out by serial hybridization of multiple
fluorophore-labeled detection oligonucleotides or via in
situ sequencing. In situ sequencing of padlock probes
has been used for highly multiplexed analysis of
mRNA expression [40,69].
Retrieving Information from Images
Visually interpreting the histology of a tissue section
requires years of training, and the value of experience
is of uttermost importance. However, the evaluation is
difficult and sometimes biased, and pathologists often
disagree on diagnosis [70]. A major advantage of
classical pathologic examination is that it takes into
account gross histologic characteristics of a tumor
that sum up a huge amount of minor molecular and
topographically restricted characteristics. If a tumor is
macroscopically or microscopically invading the sero-
sa of a gastrointestinal specimen, this gives relevant,
bulk information, whatever the mutational profile of the
specific tumor might be. Even microscopic studies at
the cellular level are, at this moment, comparably
gross and maybe also highly informative because
of this: if a tumor is invading veins, this signals
hematogeneous dissemination with a high probability,
again whatever themolecular profile of the case under
scrutiny is. Pathology has, however, several limita-
tions since it is difficult to monitor a large number of
cells, and individual cells may easily be missed.
Hence, automated image analysis will provide an
important complement for the pathologists in theevaluation of tissue sections. It will provide a tool for
better characterization of the tissue and for the
identification of individual cells of defined phenotypes
to complement and not compete with the extremely
useful observations at a more “macro” level. Morpho-
logical features associated with cell state include, for
example, cell size, nucleus-to-cytoplasm ratio and
chromatin characteristics including granularity, mar-
gination, condensation and compaction. These func-
tion/morphology relationships have been extensively
used in analyses of malignant cells [71]. It has also
been shown that these features can be captured with
high stringency using automated digital image analy-
ses [72]. In addition, digital image processing and
analysis provides tools for initial characterization of
tissue samples detecting low-resolution characteris-
tics such as vascularization [73], gland shape and
distribution, tumor shape and smoothness of the
tumor–host interface [74].
Future Perspectives
With morphologic features and molecular profiles
as input, we can group tissue areas and cells
with common characteristics together using spatially
resolved high-dimensional clustering [75,76]. Com-
bining more and more features in the analysis, more
and more cell types and functional states can be
identified, again without loosing the organizational
level given by classical pathologic examination.
Instead of discrete classes of cell populations, the
analysis will produce a continuum of clusters linked
by the differentiation lineage from where they arose.
This type of analysis has the potential to determine
the functional state of each individual cell and will be
essential to detect, for example, single cancer cells
invading the surrounding stroma. However, it will not
be able to discern what signals underlay these
functional states, that is, towhat extent is the functional
states regulated by the genomic/epigenomic blueprint
versus cell–cell contacts and secreted factors from
adjacent cells. When the spatial information is taken
into account, we can also discern the functional states
of the surrounding cells. Knowing the functional state
of each cell together with the architecture of the
tissue is a prerequisite to perform analysis of cellular
communication, which is the basis for understanding
microecology. Further, by combining analysis of
signaling pathway activity status with genotyping,
that is, using padlock probes, it will be feasible also
to determine what features different subclones exhibit
and how/if this is altered when the microecology
is affected by chemotherapy. This will generate
topographically oriented information on top of
molecular and mutational data, giving coherence
and compactness to our current vision on microecol-
ogy of tumor tissue and its neighborhood relation-
ships, in the absence or in the presence of therapeutic
interventions.
2019Review: Surveillance of Tumor MicroecologyAspreviouslymentioned, anadvantageof in situPLA
and padlock probes is that RCA generates bright
discrete objects that can be enumerated using image
analysis [77]. For in situ sequencing, the spatial
localization of each individual RCA product, possibly
by using cellular staining as reference points, has to be
determined in order to decode the fluorescence
identity of every RCA products in a set of serial image
acquisitions [78]. After a set of images has been
acquired on tissue sections stained with in situ PLA
and padlock probes, the tissue sections can then be
stained with conventional immunohistofluorescence/
immunohistochemistry and hematoxylin/eosin staining
and new sets of images can be recorded. All these
different types of images, obtainedby fluorescence and
brightfield microscopy using several fields of view
stitched up to larger images, have to be lined up
correctly in order to produce an image that contains all
the information in multiple image channels (Fig. 2).
Apart from detection of RCA products, the image also
has to be partitioned into cells and other structures of
interest, such as blood vessels and glands. Information
linked to these structures, such as shape, intensity and
texture, needs to be retrieved and processed, for
example, usingmachine learning and spatial clustering
methods, to determine cell types and functional states.
Finally, all the gathered information, including cell
identities, can be visualized using pseudo-colors or by
representing different types of RCA products by color-
and shape-coded markers. The different types of
information can then be visualized using a viewer in
analogy with software to visualize satellite images
combined with street maps and traffic monitoring, forFig. 2. By overlaying pictures taking from hematoxylin/eosin
in situ PLA and padlock probes, we will be able to achieve a
tissue. Hematoxylin/eosin staining will aid in evaluating m
distinguish different cell types by expression of marker proteins
the cells while padlock probes will provide valuable informati
mutations. All this information can be combined in order to se
features.example, Google Earth. The next step in the
image-processing pipeline is to determine the
consequence a physical interaction, or close proximity
between cells, has on the molecular profiles, or
functional states, of the cells. Mapping interactions
between cells with defined molecular profiles will be
a similar task as mapping protein interactions in
systems biology. This will provide information on
cellular communications; that is, it will determine how
the molecular profiles of cells are dependent on the
cell type lineage and on the molecular profile of its
neighbors. Utilizing information on genotypes and
functional states of signaling networks, while keeping
the spatial information of each cell, will give patholo-
gists and researchers the possibility to explore tumor
microecology. One fantastic possibility with this
approach is that it generates images with several
layers of information, giving context andmomentum to
minute molecular events and comprehensive deep-
ness to “gross” pathological characteristics.
Open-access libraries of analyzed tissue sections
combining molecular profiling and with morphologi-
cal analysis by image analysis will provide valuable
reference materials for pathologists. The methods
and pipelines described herein will not replace
pathologists, but rather, these will help them in
their work and improve the analysis and decision-
making procedure. An image/knowledge library
together with efficient visualization and data explo-
ration tools would allow identification of features
shared among different patients, together with
information on the outcome, which will be important
to tailor the treatment strategies for new patients.staining and immunofluorescence with these obtained with
high level of information about different cell types within a
orphology, and immunofluorescence might be used to
. In situ PLA will give insights into protein interactions inside
on about expression of RNA transcripts and presence of
gment cells and identify populations of cells within shared
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